How Is Little Green Pharma Using Europe to Grow (ASX:LGP)?
Highlights
- Little Green Pharma shares are trading near the lower end of their yearly range this month despite record annual revenue.
- Europe has overtaken Australia as the company’s largest source of quarterly revenue, led by demand in Germany.
- Regulatory reform in Australia and a proposed merger with Cannatrek are shaping the company’s next phase.
Little Green Pharma
(ASX:LGP)
Little Green Pharma Ltd (ASX:LGP)
0.07
AUD
+0.001
1.409%
Last Updated at: 2026-09-24T04:13:00Z
is trading close to the bottom of its yearly range this month, with the Perth-based medicinal cannabis producer’s share price well below levels seen a year ago even as its latest annual report points to record revenue and a business that is increasingly driven by demand in Europe rather than at home.
A weak share price against a stronger business
Market data compiled by StockAnalysis shows Little Green Pharma shares changing hands near the lower end of their yearly range at the start of September, having fallen by roughly half over the preceding year. The stock has spent much of the past few months drifting lower, with the company’s market value shrinking from levels seen in early June.
The weakness contrasts with the operating picture presented in the annual report for the year ended March. That report described a year of strong growth and resilience, with record revenue and a sharp improvement in adjusted earnings, although the group still recorded a modest statutory loss after tax.
What the annual report showed
Revenue from ordinary activities rose by a mid-teens rate compared with the prior year, reaching a record for the company. Adjusted earnings before interest, tax, depreciation and amortisation more than doubled, a sign that scale and cost discipline are beginning to lift profitability.
Operating cash flow turned slightly positive after an outflow in the prior year, and the company ended the period with a modest cash balance supported by unused finance facilities. The swing from a statutory profit to a small loss reflected items below the earnings line, including finance charges and non-cash costs.
Europe becomes the growth engine
The most striking shift in the report is geographic. Management said European revenue exceeded Australian revenue in the most recent quarter, confirming Europe as the company’s primary growth driver. Germany remains the key market, with strong demand for pharmaceutical-grade flower supporting growth, particularly through white-label channels.
The company’s Danish facility sits at the centre of this strategy. Ongoing optimisation there is expected to reduce production costs and unlock scale benefits, and management argued that being a European-based supplier is increasingly valuable as global supply chains remain constrained and freight costs rise for competitors located outside the region.
From white label to its own brands
Much of the growth over the year came from white-label flower sales in Germany and the United Kingdom. Looking ahead, Little Green Pharma has said it intends to refocus on growing its own branded products in Europe, particularly in France, the United Kingdom and Germany.
Branded sales typically offer better margins and stronger customer relationships than white-label supply, but they also require investment in marketing, prescriber education and distribution. How quickly that transition happens is likely to influence the company’s margin profile.
France, Poland and Italy
Beyond its core European markets, the company has maintained a focus on jurisdictions with high regulatory barriers. It has taken part in the French medicinal cannabis pilot program and continues dossier preparation ahead of the expected move to a permanent framework in France, which management regards as a significant milestone.
The report also noted encouraging signs in Poland as market conditions stabilised, and initial commercial activity in Italy. The company continues to monitor developments in Spain and retains a minority interest in Trichome Pharma.
The Australian market is changing
At home, Little Green Pharma has grown through a diversified channel strategy, including distributor partnerships, clinic networks and its own operational capabilities. Its Health House business has developed into an integrated distribution and logistics arm, contributing to services revenue through expanded third-party logistics offerings.
The regulatory backdrop in Australia is evolving. The Therapeutic Goods Administration has been consulting on changes to the medicinal cannabis framework, and the company has lodged submissions supporting a more structured, quality-focused system. Management acknowledged that reforms could present near-term challenges but expects stronger oversight to favour scaled and compliant producers.
Where the company sits in the market
Little Green Pharma is a small company by market value, well outside the large benchmark indices, and its share price often moves independently of the broader All Ordinaries. Liquidity in its shares is also far thinner than in larger healthcare names, which can amplify price swings.
Readers tracking ASX Cannabis Stocks will be aware that the local sector has thinned out over recent years, with several companies suspended, delisted or absorbed. Those that remain have had to contend with falling prices, intense competition and shifting regulation, which has made scale and access to overseas markets increasingly important.
The proposed Cannatrek merger
The annual report also flagged a proposed merger with Cannatrek, another Australian medicinal cannabis group, with a vote by the company’s owners expected in late May. Management referred to the proposed combined group as being well placed to adapt to regulatory change, given its focus on quality and compliance.
Consolidation has become a recurring theme across the industry as smaller operators struggle with price pressure. In its annual report, the board said that, as the sector consolidates, it believes Little Green Pharma is well placed to pursue strategic opportunities. Readers should check the latest company announcements for the status of the transaction.
Global regulatory momentum
The annual report pointed to several international developments that could support the sector over time. Germany’s evolving framework has driven substantial growth in patient access, France has moved toward a permanent regime, and the rescheduling of medicinal cannabis in the United States after the financial year end was described as a notable development.
Management framed these changes as part of a broader transition of medicinal cannabis from a niche therapy toward a more mainstream treatment pathway. While none of these shifts guarantee commercial success, they help explain why the company has concentrated its growth ambitions in regulated European markets.
Psychedelics and other adjacent interests
Little Green Pharma has also retained a presence in the emerging psychedelics field through Reset Mind Sciences. During the year it took a measured approach there, preserving capability and monitoring regulatory developments while completing a clinical trial, rather than committing large amounts of fresh capital.
That cautious stance reflects the company’s broader priority of building a profitable core business in medicinal cannabis. For now, psychedelics remain a small option on future growth rather than a meaningful contributor to revenue, and the market is likely to judge the company mainly on its cannabis operations.
Management has also emphasised pharmaceutical-grade quality standards across its sites, a factor that matters in regulated European markets where customers, prescribers and regulators demand consistent product and strict compliance. Maintaining those standards while lowering costs will be an ongoing balancing act.
Risks the market is weighing
The share price suggests the market remains cautious. Price competition in medicinal cannabis has been intense, both in Australia and in Europe, and white-label supply can be exposed to shifts in demand from larger customers. Currency movements and freight costs also influence returns from overseas sales.
The company’s cash balance is relatively modest, even with access to unused finance facilities, and any large expansion or integration effort would need to be funded carefully. Regulatory changes in Australia could also reshape the domestic market in ways that are difficult to predict.
What to watch from here
Market data providers list an earnings update for Little Green Pharma in early October, which would give the market a fresh look at trading since the March year end and at how the European business has performed through the northern summer. Key areas of interest include the pace of European growth, progress with branded products, Danish production costs and any update on corporate activity.
For now, the company presents a contrast between an improving operating record and a share price that has continued to weaken. Whether that gap narrows is likely to depend on evidence that European growth can translate into consistent profits and cash flow.
